NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes

Existing risk prediction scores based on clinical and laboratory variables have been considered inaccurate in patients with Type 2 Diabetes Mellitus (T2DM). Circulating concentrations of natriuretic peptides have been used to aid in the diagnosis and to predict outcomes in heart failure. However, th...

Descripción completa

Detalles Bibliográficos
Autores: Malachias, Marcus V. Bolivar, Wijkman, Magnus Olof, Bertoluci, Marcello Casaccia
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:Brasil
Institución:Universidade Federal do Rio Grande do Sul (UFRGS)
Repositorio:Repositório Institucional da UFRGS
Idioma:inglés
OAI Identifier:oai:www.lume.ufrgs.br:10183/289616
Acceso en línea:http://hdl.handle.net/10183/289616
Access Level:acceso abierto
Palabra clave:Prognóstico
Biomarcadores
Peptídeos natriuréticos
Morbidade
Doenças cardiovasculares
Diabetes mellitus tipo 2
Natriuretic peptides
Biomarkers
Type 2 diabetes
Risk assessment
Cardiovascular disease
Prognosis
Morbidity
id BR_cdbdfd44fce1efdca449eb3b2065053e
oai_identifier_str oai:www.lume.ufrgs.br:10183/289616
network_acronym_str BR
network_name_str Brasil
repository_id_str
spelling 2025-04-08T06:57:47Z20221758-5996http://hdl.handle.net/10183/289616001244513Existing risk prediction scores based on clinical and laboratory variables have been considered inaccurate in patients with Type 2 Diabetes Mellitus (T2DM). Circulating concentrations of natriuretic peptides have been used to aid in the diagnosis and to predict outcomes in heart failure. However, there is a growing body of evidence for the use of natriuretic peptides measurements, mainly N-terminal pro-B-type natriuretic peptide (NT-proBNP), as a tool in risk stratification for individuals with T2DM. Studies have demonstrated the ability of NT-proBNP to improve outcomes prediction when incorporated into multivariate models. More recently, evidence has emerged of the discriminatory power of NT-proBNP, demonstrating, as a single variable, a similar and even superior ability to multivariate risk models for the prediction of death and cardiovascular events in individuals with T2DM. Natriuretic peptides are synthesized and released from the myocardium as a counter-regulatory response to increased cardiac wall stress, sympathetic tone, and vasoconstriction, acting on various systems and affecting different biological processes. In this article, we present a review of the accumulated knowledge about these biomarkers, underscoring the strength of the evidence of their predictive ability for fatal and non-fatal outcomes. It is likely that, by influencing the functioning of many organs, these biomarkers integrate information from different systems. Although not yet recommended by guidelines, measurement of natriuretic peptides, and particularly NT-proBNP, should be strongly considered in the risk stratification of individuals with T2DM.application/pdfengDiabetology & metabolic syndrome. [São Paulo]. Vol. 14 (2022), 64, 13 p.PrognósticoBiomarcadoresPeptídeos natriuréticosMorbidadeDoenças cardiovascularesDiabetes mellitus tipo 2Natriuretic peptidesBiomarkersType 2 diabetesRisk assessmentCardiovascular diseasePrognosisMorbidityNT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetesinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSMalachias, Marcus V. BolivarWijkman, Magnus OlofBertoluci, Marcello CasacciaTEXT001244513.pdf.txt001244513.pdf.txtExtracted Texttext/plain68467http://www.lume.ufrgs.br/bitstream/10183/289616/2/001244513.pdf.txt6953caeb4242a916429d4de4d6bc3036MD52ORIGINAL001244513.pdfTexto completo (inglês)application/pdf1353369http://www.lume.ufrgs.br/bitstream/10183/289616/1/001244513.pdfb441a3d833b26efa19f92e4c9976496eMD5110183/2896162025-04-11 15:49:27.566708oai:www.lume.ufrgs.br:10183/289616Repositório InstitucionalPUBhttps://lume.ufrgs.br/oai/requestlume@ufrgs.bropendoar:2025-04-11T18:49:27Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
title NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
spellingShingle NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
Malachias, Marcus V. Bolivar
Prognóstico
Biomarcadores
Peptídeos natriuréticos
Morbidade
Doenças cardiovasculares
Diabetes mellitus tipo 2
Natriuretic peptides
Biomarkers
Type 2 diabetes
Risk assessment
Cardiovascular disease
Prognosis
Morbidity
title_short NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
title_full NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
title_fullStr NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
title_full_unstemmed NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
title_sort NT-proBNP as a predictor of death and cardiovascular events in patients with type 2 diabetes
dc.creator.none.fl_str_mv Malachias, Marcus V. Bolivar
Wijkman, Magnus Olof
Bertoluci, Marcello Casaccia
author Malachias, Marcus V. Bolivar
author_facet Malachias, Marcus V. Bolivar
Wijkman, Magnus Olof
Bertoluci, Marcello Casaccia
author_role author
author2 Wijkman, Magnus Olof
Bertoluci, Marcello Casaccia
author2_role author
author
dc.subject.por.fl_str_mv Prognóstico
Biomarcadores
Peptídeos natriuréticos
Morbidade
Doenças cardiovasculares
Diabetes mellitus tipo 2
topic Prognóstico
Biomarcadores
Peptídeos natriuréticos
Morbidade
Doenças cardiovasculares
Diabetes mellitus tipo 2
Natriuretic peptides
Biomarkers
Type 2 diabetes
Risk assessment
Cardiovascular disease
Prognosis
Morbidity
dc.subject.eng.fl_str_mv Natriuretic peptides
Biomarkers
Type 2 diabetes
Risk assessment
Cardiovascular disease
Prognosis
Morbidity
description Existing risk prediction scores based on clinical and laboratory variables have been considered inaccurate in patients with Type 2 Diabetes Mellitus (T2DM). Circulating concentrations of natriuretic peptides have been used to aid in the diagnosis and to predict outcomes in heart failure. However, there is a growing body of evidence for the use of natriuretic peptides measurements, mainly N-terminal pro-B-type natriuretic peptide (NT-proBNP), as a tool in risk stratification for individuals with T2DM. Studies have demonstrated the ability of NT-proBNP to improve outcomes prediction when incorporated into multivariate models. More recently, evidence has emerged of the discriminatory power of NT-proBNP, demonstrating, as a single variable, a similar and even superior ability to multivariate risk models for the prediction of death and cardiovascular events in individuals with T2DM. Natriuretic peptides are synthesized and released from the myocardium as a counter-regulatory response to increased cardiac wall stress, sympathetic tone, and vasoconstriction, acting on various systems and affecting different biological processes. In this article, we present a review of the accumulated knowledge about these biomarkers, underscoring the strength of the evidence of their predictive ability for fatal and non-fatal outcomes. It is likely that, by influencing the functioning of many organs, these biomarkers integrate information from different systems. Although not yet recommended by guidelines, measurement of natriuretic peptides, and particularly NT-proBNP, should be strongly considered in the risk stratification of individuals with T2DM.
publishDate 2022
dc.date.issued.fl_str_mv 2022
dc.date.accessioned.fl_str_mv 2025-04-08T06:57:47Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/other
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/289616
dc.identifier.issn.pt_BR.fl_str_mv 1758-5996
dc.identifier.nrb.pt_BR.fl_str_mv 001244513
identifier_str_mv 1758-5996
001244513
url http://hdl.handle.net/10183/289616
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Diabetology & metabolic syndrome. [São Paulo]. Vol. 14 (2022), 64, 13 p.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/289616/2/001244513.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/289616/1/001244513.pdf
bitstream.checksum.fl_str_mv 6953caeb4242a916429d4de4d6bc3036
b441a3d833b26efa19f92e4c9976496e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv lume@ufrgs.br
_version_ 1853662850552168448
score 15.300724

Similares en LA Referencia